Literature DB >> 7850706

Telomerase activity and oncogenesis in giant cell tumor of bone.

H S Schwartz1, S F Juliao, M F Sciadini, L K Miller, M G Butler.   

Abstract

BACKGROUND: Benign giant cell tumor of bone (GCT) is a primary skeletal neoplasm with an unpredictable pattern of biologic aggressiveness and cytogenetic findings characterized by telomeric associations and telomeric reduction. The role of maintaining telomeric integrity is performed by telomerase. To determine if telomerase activity is present, cell extracts from fibroblasts and tumor cells from five patients with GCT were analyzed and compared with HeLa (a positive control cell line).
METHODS: Telomerase activity was detected by visualizing the extension of radioactive telomeric repeats on DNA sequencing gels. Telomere reduction was assessed using southern blot analyses of the restriction enzyme Hinf I digested DNA with a radio-labeled telomere probe.
RESULTS: Telomerase or telomerase-like activity was detected in the cell extracts from HeLa and tumor cells. However, GCT telomerase activity varied and was less than that observed in HeLa, but no activity was detected from fibroblasts. In addition, telomere reduction was seen in DNA isolated from both HeLa and GCT but not in fibroblasts or age-matched controls.
CONCLUSION: Telomere reduction and telomerase activity may be oncogenic sustaining events required to maintain the transformed phenotype seen in GCT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850706      PMCID: PMC6712575          DOI: 10.1002/1097-0142(19950301)75:5<1094::aid-cncr2820750507>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

2.  Clonality studies in giant cell tumor of bone.

Authors:  H S Schwartz; J D Eskew; M G Butler
Journal:  J Orthop Res       Date:  2002-03       Impact factor: 3.494

3.  Giant cell tumor of bone: a neoplasm or a reactive condition?

Authors:  Anwar Ul Haque; Ambreen Moatasim
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

4.  Telomerase activity in skeletal sarcomas.

Authors:  G Aue; B Muralidhar; H S Schwartz; M G Butler
Journal:  Ann Surg Oncol       Date:  1998 Oct-Nov       Impact factor: 5.344

5.  Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas.

Authors:  M G Butler; G A Dahir; L K Hedges; S F Juliao; M F Sciadini; H S Schwartz
Journal:  Cancer Genet Cytogenet       Date:  1995-11

6.  Influence of telomerase activity on bone and soft tissue tumors.

Authors:  Norifumi Umehara; Toshifumi Ozaki; Shinsuke Sugihara; Toshiyuki Kunisada; Yuki Morimoto; Akira Kawai; Keiichiro Nishida; Aki Yoshida; Takuro Murakami; Hajime Inoue
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

7.  Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.

Authors:  Seyung S Chung; Debbie Adekoya; Ikechukwu Enenmoh; Orette Clarke; Piwen Wang; Marianna Sarkyssian; Yong Wu; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.435

8.  Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells.

Authors:  Seyung S Chung; Clement Aroh; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 9.  Benign Bone Tumors: An Overview of What We Know Today.

Authors:  Sara De Salvo; Vito Pavone; Sebastiano Coco; Eleonora Dell'Agli; Chiara Blatti; Gianluca Testa
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

10.  Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy.

Authors:  Matthew R Steensma; Wakenda K Tyler; Allison G Shaber; Steven R Goldring; F Patrick Ross; Bart O Williams; John H Healey; P Edward Purdue
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.